<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00035022</url>
  </required_header>
  <id_info>
    <org_study_id>BC-01-02</org_study_id>
    <nct_id>NCT00035022</nct_id>
    <nct_alias>NCT00066235</nct_alias>
  </id_info>
  <brief_title>Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas</brief_title>
  <official_title>Phase I-II Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive (High Grade) T-Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCryst Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCryst Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if intravenous BCX-1777 can be given safely to&#xD;
      improve relapsed or refractory aggressive T-cell leukemias and lymphomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the great strides that have been made in improving the outcome with frontline&#xD;
      programs of intensive chemotherapy in patients with aggressive T-cell malignancies, the&#xD;
      prognosis with relapsed or refractory T-cell leukemias or lymphomas is poor. BCX-1777 is a&#xD;
      purine nucleoside phosphorylase (PNP) inhibitor and a potential T-cell target therapy.&#xD;
&#xD;
      The purpose of the phase I portion of the study is to determine the maximum tolerated dose&#xD;
      (MTD) of BCX-1777 and the dose to be studied in the phase II portion of the study.&#xD;
&#xD;
      The purpose of the phase II portion of the study is to determine the safety and efficacy of&#xD;
      BCX-1777 in patients with relapsed or refractory aggressive T-cell malignancies.&#xD;
&#xD;
      Patients who respond to BCX-1777 or have stable disease may be eligible to receive an&#xD;
      additional course of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <completion_date>March 2004</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>71</enrollment>
  <condition>Leukemia, Lymphocytic</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCX-1777</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously treated, relapsed or refractory aggressive T-cell malignancies (leukemias&#xD;
             and lymphomas) histologically proven with measurable disease.&#xD;
&#xD;
          -  Capable of only limited self-care, confined to bed or chair more than 50% of waking&#xD;
             hours.&#xD;
&#xD;
          -  All ages are eligible. Pediatric patients (&lt;15 years of age) are eligible to be&#xD;
             treated at a dose level previously tested in adults.&#xD;
&#xD;
          -  Adequate liver and renal function.&#xD;
&#xD;
          -  Patients with prior history of stem cell transplant if they meet all other eligibility&#xD;
             requirements.&#xD;
&#xD;
          -  Negative pregnancy test within 72 hours of study treatment in females of childbearing&#xD;
             potential.&#xD;
&#xD;
          -  Life expectancy of at least 2 months.&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          -  Active serious infection not controlled by oral or intravenous antibiotics.&#xD;
&#xD;
          -  Treatment with any investigational antileukemic agents or chemotherapy agents in the&#xD;
             last 7 days before study entry, unless full recovery from side-effects has occurred or&#xD;
             patient has rapidly progressive disease judged to be life-threatening by the&#xD;
             investigator.&#xD;
&#xD;
          -  Concurrent treatment with other anti-cancer agents.&#xD;
&#xD;
          -  Known CNS leukemia or lymphoma requiring intrathecal or craniospinal radiation&#xD;
             therapy. Lumbar puncture not required in asymptomatic patients.&#xD;
&#xD;
          -  Pregnant and/or lactating women; or fertile men or women not willing to use&#xD;
             contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah A. Thomas, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2005</verification_date>
  <study_first_submitted>May 2, 2002</study_first_submitted>
  <study_first_submitted_qc>May 2, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2002</study_first_posted>
  <last_update_submitted>January 12, 2006</last_update_submitted>
  <last_update_submitted_qc>January 12, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2006</last_update_posted>
  <keyword>Leukemia, Lymphoma, T-Cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

